Beta-3 Adrenoreceptor Agonist Mirabegron Improves Right Ventricular Function in a Rat Monocrotaline-Induced Pulmonary Hypertension Model

12 January 2026

Pedro Mendes-Ferreira, Birger Tielemans, Allard Wagenaar, Caroline Bouzin, Rui Adão, Peter Pokreisz, Delphine De Mulder, Adelino Leite-Moreira, Carmen Brás-Silva, Jean-Luc Balligand, Chantal Dessy, Marion Delcroix, Rozenn Quarck, Catharina Belge

https://doi.org/10.1002/pul2.70232

Abstract

Considering the beta-3 adrenoceptor agonist, mirabegron, may display vasodilator and cardioprotective properties, we investigated the therapeutic potential of mirabegron in monocrotaline-induced pulmonary hypertension in rats. High-dose mirabegron improved right ventricular function, and endothelium-dependent relaxation in isolated rat pulmonary arteries, suggesting that mirabegron may be beneficial in pulmonary arterial hypertension.

Read the full research letter

Other materials on this topic

12 January 2026

Bioengineering and bioprinting advances in PH research

Leading researchers showcase cutting-edge bioengineering and bioprinting technologies — from organ-on-a-chip models to 3D-printed vasculature — driving new insights into pulmonary hypertension mechanisms and therapies.

Members Only

8 January 2026

Echinacoside Improves Pulmonary Vascular Remodeling by Regulating the L- and T-Type Ca2+ Channels in the Prevention and Treatment of Pulmonary Hypertension

The typical pathology of pulmonary hypertension (PH) is characterized by pulmonary vasoconstriction and irreversible pulmonary vascular remodeling. Vascular remodeling is the process of structural changes and cellular rearrangement of blood vessels due to injury and is a significant factor in conditions such as PH.

Pulmonary Circulation

19 December 2025

Pulmonary Hypertension Community Call — December

An on-demand recording of PVRI’s December PH Community Call, featuring informal discussion on emerging science and patient-focused research in pulmonary hypertension. The session covers new insights into hypoxic PH mechanisms and exercise interventions in PAH, with expert-led moderation and open exchange.

PVRI Community Calls

12 December 2025

Living Legend: Rubin Tuder, University of Colorado

In this Living Legends in PH session, Rubin Tuder reflects on a career that has shaped modern pulmonary hypertension research. He discusses key scientific advances, including the Sugen–hypoxia rat model, and shares personal insights on discovery, mentorship, and the evolution of the PH field, joined by Paul Hassoun and Jason Hong.